Resultados de la búsqueda 1-10 of 13955 for Raised platelets

  1. Hipertensión portal - Síntomas y causas - Mayo Clinic

    Portal hypertension means high blood pressure in the system of veins that carry blood from your digestive organs to your liver.

  2. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  3. Hipertensión portal - Síntomas y causas - Mayo Clinic

    Portal hypertension means high blood pressure in the system of veins that carry blood from your digestive organs to your liver.

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  5. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  6. Neurología - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  7. Hematología - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  8. Hematología - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to learn about how platelets adhere to the blood von Willebrand factor and how known clinical mutations that result in bleeding ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  10. Hematología - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...